Status: Recruiting
Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis
This clinical study is in participants with Amyotrophic Lateral Sclerosis and is designed to evaluate the safety and tolerability of the gene therapy CTx1000.
Participants needed: 15
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Celosia Therapeutics Pty LtdUpdated: Feb 10, 2026Locations: 1
Eligibility criteria
Diagnosis of ALS in accordance with the revised El Escorial criteria and TRICALS... [+5]
Any participants with genetic forms of ALS, including C9ORF72 repeat carriers, e... [+4]